PMID- 33717260
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210316
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 21
IP  - 4
DP  - 2021 Apr
TI  - The miR-136-5p/ROCK1 axis suppresses invasion and migration, and enhances 
      cisplatin sensitivity in head and neck cancer cells.
PG  - 317
LID - 10.3892/etm.2021.9748 [doi]
LID - 317
AB  - Laryngeal squamous cell carcinoma (LSCC) and hypopharyngeal squamous cell 
      carcinoma (HPSCC) are two types of head and neck cancers with high incidence 
      rates and relatively poor prognoses. The aim of the present study was to 
      determine the effects of microRNA (miR/miRNA)-136-5p and its downstream target, 
      Rho-associated coiled-coil containing protein kinase 1 (ROCK1), on LSCC and HPSCC 
      progression and cisplatin sensitivity. The miRNA and protein expression levels in 
      head and neck cancer cell lines were evaluated using reverse 
      transcription-quantitative PCR and western blotting, respectively. MTT, wound 
      healing assays, transwell assays and flow cytometry analysis were performed to 
      measure cell properties. The binding between miR-136-5p and ROCK1 was detected 
      using a dual-luciferase reporter assay. Autophagy double-labeled adenoviral 
      infection assays were used to assess cell autophagy. The results showed that 
      miR-136-5p was expressed in LSCC and HPSCC cells. Functional experiments showed 
      that the expression of miR-136-5p in LSCC and HPSCC cells was negatively 
      correlated with cell viability, invasion and migration. Additionally, miR-136-5p 
      overexpression inhibited epithelial-mesenchymal transition, whereas miR-136-5p 
      knockdown had the opposite effect. Dual-luciferase reporter assays confirmed the 
      targeting relationship between miR-136-5p and ROCK1. miR-136-5p overexpression 
      increased the cisplatin sensitivity of LSCC and HPSCC cells by reducing cell 
      viability, as well as promoting cell apoptosis and autophagy. miR-136-5p 
      overexpression decreased the expression levels of its downstream target ROCK1 and 
      attenuated activity of the Akt/mTOR signaling pathway in cisplatin-treated LSCC 
      and HPSCC cells. Conversely, miR-136-5p knockdown increased ROCK1 levels and 
      decreased cisplatin sensitivity of the LSCC and HPSCC cells by increasing cell 
      viability and inhibiting cell apoptosis, which was reversed by ROCK1 inhibition 
      using the ROCK1 inhibitor, Y27632. Taken together, the results showed that the 
      miR-136-5p/ROCK1 axis inhibits cell invasion and migration, and increases the 
      sensitivity of LSCC and HPSCC cells to cisplatin.
CI  - Copyright: (c) Yang et al.
FAU - Yang, Bo
AU  - Yang B
AD  - Department of Otorhinolaryngology Head and Neck Surgery, The First Hospital of 
      China Medical University, Shenyang, Liaoning 110001, P.R. China.
FAU - Zang, Jian
AU  - Zang J
AD  - Department of Otorhinolaryngology Head and Neck Surgery, The First Hospital of 
      China Medical University, Shenyang, Liaoning 110001, P.R. China.
FAU - Yuan, Weili
AU  - Yuan W
AD  - Department of Oral and Maxillofacial Surgery, The Fourth Affiliated Hospital of 
      China Medical University, Shenyang, Liaoning 110032, P.R. China.
FAU - Jiang, Xuejun
AU  - Jiang X
AD  - Department of Otorhinolaryngology Head and Neck Surgery, The First Hospital of 
      China Medical University, Shenyang, Liaoning 110001, P.R. China.
FAU - Zhang, Fang
AU  - Zhang F
AD  - Department of Otorhinolaryngology Head and Neck Surgery, The Fourth Affiliated 
      Hospital of China Medical University, Shenyang, Liaoning 110032, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20210203
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC7885062
OTO - NOTNLM
OT  - Rho-associated coiled-coil containing protein kinase 1
OT  - cell invasion
OT  - cell migration
OT  - cisplatin sensitivity
OT  - hypopharyngeal squamous cell carcinoma
OT  - laryngeal squamous cell carcinoma
OT  - microRNA-136-5p
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
PMCR- 2021/02/03
CRDT- 2021/03/15 06:59
PHST- 2020/03/04 00:00 [received]
PHST- 2020/12/15 00:00 [accepted]
PHST- 2021/03/15 06:59 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
PHST- 2021/02/03 00:00 [pmc-release]
AID - ETM-0-0-09748 [pii]
AID - 10.3892/etm.2021.9748 [doi]
PST - ppublish
SO  - Exp Ther Med. 2021 Apr;21(4):317. doi: 10.3892/etm.2021.9748. Epub 2021 Feb 3.